Matches in SemOpenAlex for { <https://semopenalex.org/work/W2014692241> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2014692241 endingPage "3309" @default.
- W2014692241 startingPage "3309" @default.
- W2014692241 abstract "We were interested to read the editorial by Dr Carde1, which referred to our article2 that reported the results of the United Kingdom Lymphoma Group LY09 study in advanced Hodgkin's lymphoma. The editorial may have given the impression that our study was a randomized comparison of three regimens, which is not the case. A standard arm of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) was used, and investigators elected in advance whether to randomize against the alternating or hybrid regimen. Thus, it is not legitimate to make direct comparison of the two multidrug arms. It is also difficult to compare the overall results in this study to the Italian trial reported in the same issue by Gobbi et al3, which included a more favorable group of patients among whom only 11% of patients were in International Prognostic Score group 4 to 7, compared with 19% in the UK study. The measure of 65% progression-free survival at 5 years cited by Dr Carde refers only to patients in stages III/IV, whereas for the UK study as a whole the figure is 73%. The interpretation of information regarding the use of radiotherapy in the two parallel randomizations is problematic. Dr Carde suggests that a comparison can be made between the two standard ABVD groups, with the more frequent use of eight cycles in the centers randomizing against alternating treatment apparently giving marginally better freedom from progression results than those seen in the hybrid randomization, where it was more common to use six cycles followed by radiotherapy. Such data must be interpreted with caution, especially because the patients in the hybrid randomization were more likely to have bulky mediastinal disease and systemic symptoms, suggesting a worse prognostic group. We contend that such an effect may be due to patient selection rather than the use of radiotherapy or fewer cycles of ABVD. Finally, Dr Carde has made a provocative analysis of the data, correlating freedom from progression with intended, rather than actual doses delivered. This may be helpful in terms of generating hypotheses to be tested in future studies but does not necessarily explain observed outcomes in the LY09 trial." @default.
- W2014692241 created "2016-06-24" @default.
- W2014692241 creator A5007119947 @default.
- W2014692241 creator A5011398209 @default.
- W2014692241 creator A5023188445 @default.
- W2014692241 creator A5024050303 @default.
- W2014692241 creator A5059261043 @default.
- W2014692241 creator A5082102746 @default.
- W2014692241 date "2006-07-10" @default.
- W2014692241 modified "2023-10-16" @default.
- W2014692241 title "Comparison of Outcomes in Studies of Advanced Hodgkin's Lymphoma" @default.
- W2014692241 cites W2065620512 @default.
- W2014692241 cites W2085143233 @default.
- W2014692241 cites W2107089248 @default.
- W2014692241 cites W2142226790 @default.
- W2014692241 cites W2142757611 @default.
- W2014692241 cites W2148916166 @default.
- W2014692241 cites W2262902984 @default.
- W2014692241 doi "https://doi.org/10.1200/jco.2006.06.2976" @default.
- W2014692241 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16829655" @default.
- W2014692241 hasPublicationYear "2006" @default.
- W2014692241 type Work @default.
- W2014692241 sameAs 2014692241 @default.
- W2014692241 citedByCount "0" @default.
- W2014692241 crossrefType "journal-article" @default.
- W2014692241 hasAuthorship W2014692241A5007119947 @default.
- W2014692241 hasAuthorship W2014692241A5011398209 @default.
- W2014692241 hasAuthorship W2014692241A5023188445 @default.
- W2014692241 hasAuthorship W2014692241A5024050303 @default.
- W2014692241 hasAuthorship W2014692241A5059261043 @default.
- W2014692241 hasAuthorship W2014692241A5082102746 @default.
- W2014692241 hasBestOaLocation W20146922411 @default.
- W2014692241 hasConcept C126322002 @default.
- W2014692241 hasConcept C143998085 @default.
- W2014692241 hasConcept C2779338263 @default.
- W2014692241 hasConcept C2992779791 @default.
- W2014692241 hasConcept C71924100 @default.
- W2014692241 hasConceptScore W2014692241C126322002 @default.
- W2014692241 hasConceptScore W2014692241C143998085 @default.
- W2014692241 hasConceptScore W2014692241C2779338263 @default.
- W2014692241 hasConceptScore W2014692241C2992779791 @default.
- W2014692241 hasConceptScore W2014692241C71924100 @default.
- W2014692241 hasIssue "20" @default.
- W2014692241 hasLocation W20146922411 @default.
- W2014692241 hasLocation W20146922412 @default.
- W2014692241 hasOpenAccess W2014692241 @default.
- W2014692241 hasPrimaryLocation W20146922411 @default.
- W2014692241 hasRelatedWork W1756508042 @default.
- W2014692241 hasRelatedWork W2050115670 @default.
- W2014692241 hasRelatedWork W2052404185 @default.
- W2014692241 hasRelatedWork W2090594897 @default.
- W2014692241 hasRelatedWork W2125749452 @default.
- W2014692241 hasRelatedWork W2420129157 @default.
- W2014692241 hasRelatedWork W2440709063 @default.
- W2014692241 hasRelatedWork W4240491315 @default.
- W2014692241 hasRelatedWork W4248583329 @default.
- W2014692241 hasRelatedWork W4307424962 @default.
- W2014692241 hasVolume "24" @default.
- W2014692241 isParatext "false" @default.
- W2014692241 isRetracted "false" @default.
- W2014692241 magId "2014692241" @default.
- W2014692241 workType "article" @default.